Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma
- 30 September 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 95 (3) , 259-265
- https://doi.org/10.1016/s1081-1206(10)61223-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Can Guideline-defined Asthma Control Be Achieved?American Journal of Respiratory and Critical Care Medicine, 2004
- Low-Dose Inhaled Corticosteroids and the Prevention of Death from AsthmaNew England Journal of Medicine, 2000
- Efficacy and Safety of Inhaled CorticosteroidsAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Inhaled steroids and the risk of hospitalization for asthmaJAMA, 1997
- A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trialJournal of Allergy and Clinical Immunology, 1992
- Role of Leukotrienes in Exercise-induced Asthma: Inhibitory Effect of ICI 204219, a Potent Leukotriene D4Receptor AntagonistAmerican Review of Respiratory Disease, 1992
- Effect of an Inhaled Corticosteroid on Airway Inflammation and Symptoms in AsthmaAmerican Review of Respiratory Disease, 1992
- Dexamethasone Does Not Inhibit the Release of Mediators from Human Mast Cells Residing in Airway, Intestine, or SkinAmerican Review of Respiratory Disease, 1989
- Terfenadine in exercise induced asthma.BMJ, 1984
- Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells.Journal of Clinical Investigation, 1983